-Reduced obesity biomarkers: body weight by 69.7%, liver weight by 19.6%, and adipose weight by 58.3%.-Inflammatory markers decreased significantly, with plasma insulin reduced by 88%, leptin by 92%, resistin by 27%, and glucagon by 97%.-Metabolic biomarkers improved, including a 25.4% decrease in blood glucose, 62.9% reduction in triglycerides, 37.6% reduction in LDL cholesterol, and an 82.3% improvement in the HOMA-IR index.-Modulated the gut microbiome, reducing the Firmicutes/Bacteroidetes ratio by 65.6%. This evidence concerns the gene INS and obesity disorder.